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Relevance of tumor infiltrating lymphocytes as a prognostic factors in patients with portal vein 
embolisation (PVE) and patients with PVE and administration of autologous stem cells 
 
Background: low future liver remnant volume (FLRV) is the cause of why 75% of patients with 
colorectal liver metastases (CLM) are primarily inoperable. Portal vein embolisation (PVE) helps to 
increase FLRV and so increase the operability. But PVE fails in almost 40 % of patients. Usage of stem 
cells (SCs) could be the way how to support the effect of PVE. Currently, there are studies of 
interactions of the immune system and malignancies. We do not know about papers focused on 
relations of the immune system and CLM in patients treated by PVE. There were not described 
interactions of ABC transporters and CLM at patients after PVE was performed too. 
Aims: the aim of this dissertation was to verify the effect of PVE and intraportal administration of SCs 
on the growth of FLRV and progression of the CLM. Other aims were to evaluate the tumor 
infiltrating lymphocytes, ABCC10 and ABCC11 transportes in patients treated by surgery for CLM 
after PVE and their clinical relevances. 
Methods: intraportal administration of SCs after PVE and their effect was explored in a group of 63 
patients (43 patients with PVE alone, 20 in the group PVE with SCs). FLRV and volume of CLM were 
assessed from CT scans. Their growth was observed also in relation with resectability, disease free 
interval (DFI) and overal survival (OS). The cohort of 101 patients was used for assessement of tumor 
infiltrating lymphocytes (PVE 26 patients, PVE and SCs 13 patients, 62 patients with primarily 
resectable CLM). We assessed numbers and localization of TILs – peritumoral (PTL), intratumoral 
(ITL), intrastromal (ISL) and Crohn like infiltration were assessed. Imunohistological staining for 
CD4+,CD8+,CD25+ and FoxP3+ lymphocytes (TILs) and for CD57+ and CD86+ cells and Granzym B was 
used. Serpin B was assessed in the cancer cells. The ratio between TILs was also focused. Histological 
and microscopical examination for ABCC10 and ABCC11 transporters was performed in 86 patients 
(23 with PVE, 13 with PVE and SCs and 54 with primarily resectable) 
Results: study did not prove significant acceleration of FLRV growth after SCs administration. The 
fastest growth was observed in patients with initial FLRV lower than 30 %. Growth of VLM was not 
accelerated. Patients with administered SCs had lower number of explorative laparotomies and 
extrahepatal metastases during follow up. OS after resection was comparable to patients with PVE 
and primarily resected. The TILs assessement did not prove activation of cytotoxic reaction. Patients 
with PVE had higher levels of regulatory T cells lymphocytes (CD25+, FoxP3+) (T reg). We observed 
lower levels of CD4+ in the patients with PVE and SCs administration. The diferences were also 
observed in ITL, ISL and Crohn like infiltration. CD4+ PTL infiltration was lower in all patients with PVE. 
High infiltration of CD4+ and ISL infiltration were connected with early recurrency of the disease in all 
patients with PVE. TILs ratio showed higher infiltration of maturated T reg in all patients with PVE. 
Higher ratio FoxP3/CD25 decreased risk of recurrency in all resected patients. CD8/CD4 was a 
negative prognostic factor of the primarily resectable patients, because increasing ratio decreased 
DFI. Assessement of ABCC10 and ABCC11 did not prove significant diferences between observed 
groups. 
Conclusion: PVE is beneficial for patients with primarily unresectable CLM. Patients with intraportal 
administration of SCs had lower number of exploratory laparotomies and extrahepatal metastases 
during follow up. The cause of this situation would be the object of further research. Study did not 
prove activation of cytotoxic immunity at CLM. T reg could be a supporting factor for liver atrophy in 
the liver lobe, where the occlusion of the portal vein was performed. Higher ratio FoxP3/CD25 was a 
positive prognostic factor that increased DFI in patients with liver resection for CLM. 
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